Reynolds Salerno, PhD, had a front row view into the federal government’s response, both to the SARS-CoV-2 pandemic and the recent monkeypox outbreak. As Director of the Division of Laboratory Systems (DLS) at the U.S. Centers for Disease Control and Prevention (CDC), Salerno played an instrumental role in how diagnostic testing was provided during recent public health emergencies.
In this exclusive interview with The Dark Report, Salerno explains why the clinical laboratory and public health worlds will come together and how that relationship has been strained in the past. He also discusses possible revisions to the Clinical Laboratory Improvement Amendments of 1988 (CLIA), previewing Clinical Laboratory Improvement Advisory Committee (CLIAC) recommendations that he considers could be significant reforms to CLIA.
As Salerno notes, “I anticipate that CLIAC will begin to pressure the federal government to make more substantive changes to the CLIA regulations.”
Elsewhere in the issue, The Dark Report:
- Looks at how U.S. hospitals are poised to lose billions of dollars this year and what that means for clinical laboratory managers.
- Explores why revisited testimony from the trial of ex-Theranos CEO Elizabeth Holmes paints a more detailed picture of CLIA lab director responsibilities.
- Details what a possible merger of Qiagen and Bio-Rad Laboratories might mean for in vitro diagnostics customers.
- Reviews Ravgen’s $272.5 million jury verdict over Labcorp regarding genetic testing patent infringements.
All of these intelligence briefings and more are available to subscribers of The Dark Report. If you’re not a subscriber, try our free, 14-day trial.
